MedTrace Logo

A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults

NCT07059403 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-08-24

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, multiple-ascending-dose study of SN2001 in healthy adult subjects. The study is designed to evaluate the safety, tolerability and immunogenicity of SN2001.

Conditions

  • Chronic Hepatitis B Infection

Interventions

BIOLOGICAL

SN2001

100 µg, for subcutaneous (SC) injection

BIOLOGICAL

SN2001

200 µg, for subcutaneous (SC) injection

BIOLOGICAL

SN2001

300 µg, for subcutaneous (SC) injection

Sponsors & Collaborators

  • Chimivac INC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-19
Primary Completion
2027-04-30
Completion
2027-04-30
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07059403 on ClinicalTrials.gov